Should a urine culture with 15,000 CFU/mL (colony-forming units per milliliter) Nakaseomyces glabratus (formerly Candida glabrata) be treated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of 15,000 CFU/mL Nakaseomyces glabratus in Urine

In most cases, 15,000 CFU/mL of Nakaseomyces glabratus (formerly Candida glabrata) in urine should NOT be treated with antifungal agents unless the patient has specific high-risk features for disseminated infection.

Primary Recommendation

The IDSA 2016 Candidiasis Guidelines provide clear direction: antifungal treatment is NOT recommended for candiduria unless the patient belongs to a high-risk group 1. The guideline explicitly states this as a strong recommendation, emphasizing that most candiduria represents colonization rather than true infection.

High-Risk Patients Who REQUIRE Treatment

Treatment is indicated ONLY if the patient falls into one of these categories:

  • Neutropenic patients - treat as candidemia 1
  • Very low-birth-weight infants (<1500 g) - treat as candidemia 1
  • Patients undergoing urologic manipulation - treat prophylactically with fluconazole 400 mg daily OR amphotericin B deoxycholate 0.3-0.6 mg/kg daily for several days before and after the procedure 1

First Priority: Remove Predisposing Factors

The most important intervention is elimination of predisposing factors, particularly indwelling bladder catheters 1. This is a strong recommendation and should be attempted whenever feasible. Simply removing the catheter often resolves candiduria without antifungal therapy.

Why This Colony Count Doesn't Automatically Warrant Treatment

The 15,000 CFU/mL count is below traditional thresholds and particularly problematic to interpret:

  • Colony counts in catheterized patients cannot reliably differentiate infection from colonization 1
  • Research shows that even patients with bacteremia and true UTI can have counts <100,000 CFU/mL 2, but this applies to bacterial infections
  • For fungal infections, the IDSA guidelines do not use specific colony count thresholds to determine treatment necessity 1
  • The presence of candiduria, regardless of count, primarily indicates colonization in non-high-risk patients 1

If Treatment IS Indicated (High-Risk Patient)

For symptomatic cystitis or pyelonephritis in high-risk patients with N. glabratus:

First-line approach:

  • Determine fluconazole susceptibility first
  • If fluconazole-susceptible: oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks for cystitis 1 or 200-400 mg daily for pyelonephritis 1

For fluconazole-resistant N. glabratus (common with this species):

  • Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1
  • OR oral flucytosine 25 mg/kg 4 times daily for 7-10 days 1
  • For pyelonephritis: can combine amphotericin B with flucytosine 1

Critical Caveat About N. glabratus

N. glabratus has intrinsically reduced susceptibility to fluconazole and increasing resistance to echinocandins 3, 4. This species is particularly challenging because:

  • It rapidly develops multidrug resistance 5, 4
  • Azole resistance is common in Europe and worldwide 3
  • Echinocandins do NOT achieve adequate urinary concentrations and should not be used for urinary tract infections 1

Common Pitfall to Avoid

The most common error is treating asymptomatic candiduria in non-high-risk patients 6. A 1999 study found that 60% of clinicians initiated antifungal therapy for candiduria without documenting infection or assessing risk factors, and often based treatment on a single culture 6. This practice:

  • Does not follow evidence-based guidelines
  • Promotes antifungal resistance
  • Provides no clinical benefit
  • Wastes healthcare resources

Algorithm for Decision-Making

  1. Is the patient neutropenic, a very low-birth-weight infant, or undergoing urologic procedures?

    • YES → Treat as outlined above
    • NO → Proceed to step 2

  2. Does the patient have an indwelling catheter?

    • YES → Remove catheter if feasible; do NOT treat with antifungals
    • NO → Proceed to step 3

  3. Does the patient have symptoms of cystitis or pyelonephritis (dysuria, frequency, urgency, flank pain, fever)?

    • NO → Do NOT treat; this is colonization
    • YES → Consider treatment only if symptoms are clearly attributable to candiduria and not another cause

  4. If treatment is warranted, obtain susceptibility testing before selecting therapy given N. glabratus's high resistance rates 3

References

Related Questions

How should I manage a patient with a urine culture growing Streptococcus mitis/oralis group at 10,000–25,000 colony‑forming units per milliliter?
What does a urine culture result of less than 10,000 colony-forming units per milliliter (cfu/ml) indicate in a patient with a suspected urinary tract infection (UTI)?
Is a urine culture showing Lactobacillus species at 30,000 CFU/mL clinically significant, and should it be treated?
In a 40-year-old woman, does a clean‑catch urine culture with 15,000 CFU/mL Enterococcus faecalis indicate a clinically significant urinary tract infection?
What does a significant number of colonies in a urine culture indicate and what is the appropriate management?
What does an albumin of 3.8 g/dL, alkaline phosphatase of 173 U/L, creatinine of 1.1 mg/dL, and C‑reactive protein of 33 mg/L indicate, and what further evaluation is recommended?
What are the possible causes of increased sexual arousal in an adolescent female?
What is the pathogenesis of bone cement implantation syndrome?
Do patients still experience menstrual periods while using a Mirena (levonorgestrel-releasing intrauterine system) IUD?
If natural desiccated thyroid (NDT) becomes unavailable and my patient does not respond well to levothyroxine, what alternative therapy should I transition them to?
What is the appropriate loading dose of enoxaparin (Lovenox) for therapeutic anticoagulation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.